A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-06-30

Study Completion Date

2010-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate how common it is that patients using Symibort SMART take high average daily doses that are not considered appropriate by their physician (overuse) or are hospitalised due to their asthma at least partly due to underuse.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchial Asthma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

pharmaceopidemiological Symbicort SMART GPRD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Asthma diagnosis, patient registered with the prescribing physician for at least one year before the qualifying prescription of Symbicort, prescription of Symbicort SMART after UK launch of the concept

Exclusion Criteria

* None

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca Pharmaceuticals

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Catriona McMahon, MD

Role: PRINCIPAL_INVESTIGATOR

AZ UK MC

Tomas Andersson, MD

Role: STUDY_DIRECTOR

AZ R&D Lund

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GPRD

Identifier Type: -

Identifier Source: secondary_id

D5890C00017